Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

M. Mau-Sorensen; M. van Bussel; M. Kuipers; D. L. Nielsen; H. M. Verheul; P. Aftimos; M. J.A. de Jonge; B. van Triest; J. Falkenius; J. Debus; E. Troost; M. Samuels; B. Sarholz; V. Budach; S. Goel; G. Locatelli; P. F. Geertsen

doi:https://doi.org/10.1093/annonc/mdy303.015

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

M. Mau-Sorensen, M. van Bussel, M. Kuipers, D. L. Nielsen, H. M. Verheul, P. Aftimos, M. J.A. de Jonge, B. van Triest, J. Falkenius, J. Debus, E. Troost, M. Samuels, B. Sarholz, V. Budach, S. Goel, G. Locatelli, P. F. Geertsen

Research output: Contribution to journal › Article › Academic › peer-review

58 Citations (Scopus)

Original language	English
Pages (from-to)	viii654
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy303.015
Publication status	Published - 1 Oct 2018

Access to Document

https://doi.org/10.1093/annonc/mdy303.015

Cite this

Mau-Sorensen, M., van Bussel, M., Kuipers, M., Nielsen, D. L., Verheul, H. M., Aftimos, P., de Jonge, M. J. A., van Triest, B., Falkenius, J., Debus, J., Troost, E., Samuels, M., Sarholz, B., Budach, V., Goel, S., Locatelli, G., & Geertsen, P. F. (2018). Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii654. https://doi.org/10.1093/annonc/mdy303.015

@article{46adb21c12224fac8589cf1fa493e9a4,

title = "Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials",

author = "M. Mau-Sorensen and {van Bussel}, M. and M. Kuipers and Nielsen, {D. L.} and Verheul, {H. M.} and P. Aftimos and {de Jonge}, {M. J.A.} and {van Triest}, B. and J. Falkenius and J. Debus and E. Troost and M. Samuels and B. Sarholz and V. Budach and S. Goel and G. Locatelli and Geertsen, {P. F.}",

year = "2018",

month = oct,

day = "1",

doi = "https://doi.org/10.1093/annonc/mdy303.015",

language = "English",

volume = "29",

pages = "viii654",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Mau-Sorensen, M, van Bussel, M, Kuipers, M, Nielsen, DL, Verheul, HM, Aftimos, P, de Jonge, MJA, van Triest, B, Falkenius, J, Debus, J, Troost, E, Samuels, M, Sarholz, B, Budach, V, Goel, S, Locatelli, G & Geertsen, PF 2018, 'Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii654. https://doi.org/10.1093/annonc/mdy303.015

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials. / Mau-Sorensen, M.; van Bussel, M.; Kuipers, M. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii654.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814

T2 - Results from two phase I trials

AU - Mau-Sorensen, M.

AU - van Bussel, M.

AU - Kuipers, M.

AU - Nielsen, D. L.

AU - Verheul, H. M.

AU - Aftimos, P.

AU - de Jonge, M. J.A.

AU - van Triest, B.

AU - Falkenius, J.

AU - Debus, J.

AU - Troost, E.

AU - Samuels, M.

AU - Sarholz, B.

AU - Budach, V.

AU - Goel, S.

AU - Locatelli, G.

AU - Geertsen, P. F.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081271592&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/annonc/mdy303.015

DO - https://doi.org/10.1093/annonc/mdy303.015

M3 - Article

C2 - 32137781

SN - 0923-7534

VL - 29

SP - viii654

JO - Annals of oncology

JF - Annals of oncology

ER -

Mau-Sorensen M, van Bussel M, Kuipers M, Nielsen DL, Verheul HM, Aftimos P et al. Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii654. doi: https://doi.org/10.1093/annonc/mdy303.015

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

Access to Document

Other files and links

Cite this